tradingkey.logo
搜尋

ANI Pharmaceuticals Inc

ANIP
添加自選
79.240USD
-1.190-1.48%
收盤 07-31 16:00美東報價延遲15分鐘
1.80B總市值
19.26本益比TTM

ANI Pharmaceuticals Inc

79.240
-1.190-1.48%
查看詳細走勢圖
TradingKey 圖表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-1.48%

5天

+2.05%

1月

-4.59%

6月

-0.95%

今年開始到現在

+0.38%

1年

+23.95%

關鍵數據
79.650今開
80.380最高
205.18K成交量
19.26本益比TTM
7.42本益比動
--股利TTM
0.91%換手率
80.430昨收
78.240最低
13.56M成交額
虧損本益比靜
3.52市淨率
0.00%股息率 TTM
6.79%ROA
99.50052週最高
0.82量比
-20.15M淨利潤
22.47M總股本
4.1138每股盈餘TTM
0.45Beta
17.11%ROE
57.33052週最低
2.66%振幅
51.78%毛利率
1.80B總市值
-2.77回報/風險
1.96%風險率

TradingKey ANI Pharmaceuticals Inc股票評分

單位: USD 更新時間: 2026-07-31

操作建議

ANI Pharmaceuticals Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在藥品行業排名10/155位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為109.29。中期看,股價處於平穩狀態。近一個月,市場表現較差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

ANI Pharmaceuticals Inc評分

相關信息

行業排名
10 / 155
全市場排名
38 / 4281
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
極度看好

ANI Pharmaceuticals Inc亮點

亮點風險
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
業績高增長
公司營業收入穩步增長,連續3年增長81.46%
利潤高增長
公司淨利潤處於行業前列,最新年度總收入883.37M美元
業績轉盈
公司業績轉盈,最新年度盈利美元
估值合理
公司最新PE估值19.26,處於3年歷史合理位
機構加倉
最新機構持股23.15M股,環比增加0.25%
約翰·胡斯曼持倉
明星投資者約翰·胡斯曼持倉,最新持倉49.41K股

分析師目標

基於 8 分析師
買入
評級
109.286
目標均價
+37.92%
漲幅空間

ANI Pharmaceuticals Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

收益預測

分析師評級

基於 8 分析師
買入
評級
109.286
目標均價
+37.92%
漲幅空間
強力買入
買入
持有
賣出
強力賣出

同行比較

160
總數
6
中位數
9
平均值
公司名稱
評級分佈
分析師數
ANI Pharmaceuticals Inc
ANIP
8
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
輝瑞
PFE
32
艾伯維
ABBV
32
1
2
3
...
32

技術指標

技術指標
賣出(4)
中性(3)
買入(0)
指標
數值
方向
MACD(12,26,9)
-0.000
賣出
RSI(14)
45.744
中性
STOCH(KDJ)(9,3,3)
60.257
中性
ATR(14)
2.299
高波動
CCI(14)
-17.640
中性
Williams %R
56.990
賣出
TRIX(12,20)
-0.172
賣出
StochRSI(14)
29.901
賣出
移動平均線
賣出(5)
中性(0)
買入(1)
指標
數值
方向
MA5
80.172
賣出
MA10
79.152
買入
MA20
80.837
賣出
MA50
81.115
賣出
MA100
79.439
賣出
MA200
81.244
賣出

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

ANI Pharmaceuticals Inc簡介

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
公司代碼ANIP
公司ANI Pharmaceuticals Inc
CEOLalwani (Nikhil Suresh)
網址https://www.anipharmaceuticals.com/

公司股東

持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
10.76%
Meridian Venture Partners
4.46%
Vanguard Capital Management, LLC
3.62%
State Street Investment Management (US)
3.20%
Millennium Management LLC
2.37%
其他
75.58%

常見問題

ANI Pharmaceuticals Inc(ANIP)的當前股價是多少?

ANI Pharmaceuticals Inc(ANIP)的當前股價是 79.24。

ANI Pharmaceuticals Inc 的股票代碼是什麼?

ANI Pharmaceuticals Inc的股票代碼是ANIP。

ANI Pharmaceuticals Inc股票的52週最高點是多少?

ANI Pharmaceuticals Inc股票的52週最高點是99.50。

ANI Pharmaceuticals Inc股票的52週最低點是多少?

ANI Pharmaceuticals Inc股票的52週最低點是57.33。

ANI Pharmaceuticals Inc的市值是多少?

ANI Pharmaceuticals Inc的市值是1.78B。

現在ANI Pharmaceuticals Inc(ANIP)的股票是買入、持有還是賣出?

根據分析師評級,ANI Pharmaceuticals Inc(ANIP)的總體評級為買入,目標價格為109.29。

ANI Pharmaceuticals Inc(ANIP)股票的每股收益(EPS TTM)是多少

ANI Pharmaceuticals Inc(ANIP)股票的每股收益(EPS TTM)是3.50。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有